Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

48.37
-0.5200-1.06%
Pre-market: 48.600.2300+0.48%05:03 EDT
Volume:673.86K
Turnover:32.88M
Market Cap:3.36B
PE:-11.97
High:49.85
Open:48.91
Low:48.19
Close:48.89
52wk High:71.50
52wk Low:8.73
Shares:69.37M
Float Shares:57.53M
Volume Ratio:0.70
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0399
EPS(LYR):-3.4602
ROE:-157.61%
ROA:-15.72%
PB:10.35
PE(LYR):-13.98

Loading ...

uniQure Q1 EPS $(0.85), Inline, Sales $3.562M Miss $5.223M Estimate

Benzinga Earnings
·
May 05

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

GlobeNewswire
·
May 05

A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA

Simply Wall St.
·
May 04

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 01

uniQure price target raised to $37 from $31 at Chardan

TIPRANKS
·
May 01

Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment

MT Newswires Live
·
May 01

uniQure expects UK MHRA filing for AMT-130 in Huntington’s disease in Q3 2026

Reuters
·
Apr 30

uniQure (QURE) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Apr 29

Earning Preview: uniQure NV Q1 revenue is expected to decrease by 16.75%, and institutional views are cautious

Earnings Agent
·
Apr 29

uniQure to Announce First Quarter 2026 Financial Results

GlobeNewswire
·
Apr 28

uniQure call volume above normal and directionally bullish

TIPRANKS
·
Apr 18

uniQure put volume heavy and directionally bearish

TIPRANKS
·
Apr 11

uniQure put volume heavy and directionally bearish

TIPRANKS
·
Apr 08

uniQure (QURE) Faces FDA Rebuke, Lawsuits Over AMT-130 Disclosures Is Its Credibility at Risk?

Simply Wall St.
·
Apr 06

uniQure Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Mar 23

Uniqure Nv : Barclays Cuts Target Price to $25 From $31

THOMSON REUTERS
·
Mar 23

uniQure (QURE) Receives a Hold from Barclays

TIPRANKS
·
Mar 23

uniQure faces securities class action over AMT-130 FDA disclosures

Reuters
·
Mar 19

UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh

Simply Wall St.
·
Mar 12

Uniqure Nv : Mizuho Raises to Outperform From Neutral; Raises Target Price to $35 From $12

THOMSON REUTERS
·
Mar 11